AKTX - アカリ・セラピュ―ティクス (Akari Therapeutics Plc) アカリ・セラピュ―ティクス

 AKTXのチャート


 AKTXの企業情報

symbol AKTx
会社名 Akari Therapeutics PLC (アカリ・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Akari Therapeutics Plc formerly Celsus Therapeutics Plc is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5) including paroxysmal nocturnal hemoglobinuria Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome. Its lead drug Coversin a complement inhibitor acts on complement C5 preventing release of C5a and formation of C5b-9. Coversin is a recombinant small protein derived from a protein discovered in the saliva of the Ornithodoros moubata tick where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response. It is conducting Phase Ib clinical trial of Coversin. It focuses on rare and orphan diseases including disease states spanning hematology nephrology transplantation neurology and ophthalmology.   アカリ・セラピュ―ティクスはイギリスのバイオ医薬品企業。臨床段階で、難病に対する治療薬の開発・商業化に取り組む。自己免疫の異常に起因するギラン・バレ―症候群に対するC5モノクロナ―ル抗体治療薬、また、発作性夜間ヘモグロビン尿症の治療薬の開発・商業化にも取り組む。同社パイプラインには「C5a」と「C5b-9」を含む。本社所在地は米国ニューヨーク。   Akari is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically for the treatment of rare and orphan diseases, in particular those where the complement (C5) or leukotriene (LTB4) systems, or both complement and leukotrienes together, play a primary role in disease progression. Akari's lead drug candidate, nomacopan (formerly known as Coversin), is a C5 complement inhibitor that also independently and specifically inhibits leukotriene B4 (LTB4) activity.
本社所在地 75/76 Wimpole Street London 10018 GBR
代表者氏名 Ray Prudo レイプルード
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +44 20-8004-0261
設立年月日 38261
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 17人
url www.akaritx.com
nasdaq_url https://www.nasdaq.com/symbol/aktx
adr_tso 15208377
EBITDA EBITDA(百万ドル) -31.69758
終値(lastsale) 2.05
時価総額(marketcap) 31177172.85
時価総額 時価総額(百万ドル) 32.19213
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 17.12219
当期純利益 当期純利益(百万ドル) -31.85552
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Akari Therapeutics PLC (ADR) revenues was not reported. Net loss applicable to common stockholders decreased 27% to $9.4M. Lower net loss reflects Research and development costs decrease of 37% to $6.1M (expense) Changes in fair value of option and warr increase of 5% to $2.8M (income) Interest income increase of 71% to $132K (income).

 AKTXのテクニカル分析


 AKTXのニュース

   Akari Therapeutics (NASDAQ:AKTX) Stock Price Passes Above 50 Day Moving Average of $1.62  2021/12/24 07:54:41 Dakota Financial News
Akari Therapeutics, Plc (NASDAQ:AKTX)s stock price crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $1.62 and traded as high as $1.64. Akari Therapeutics shares last traded at $1.54, with a volume of 75,065 shares traded. The company has a market cap of $73.30 million, []
   Akari Therapeutics reports Q3 results  2021/12/03 12:55:18 Seeking Alpha
   Akari Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Clinical Progress  2021/12/03 12:45:00 Intrado Digital Media
NEW YORK and LONDON, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced its financial results for the third quarter of 2021 and recent clinical progress.
   Akari Therapeutics Presents New Data Revealing Potential Mechanism of Action Driving Serious Exacerbations Across Lung Disorders  2021/12/01 13:30:00 Intrado Digital Media
Data suggest potential therapeutic role for nomacopan in exacerbations in severe lung conditions such as COPD and COVID pneumonia Data suggest potential therapeutic role for nomacopan in exacerbations in severe lung conditions such as COPD and COVID pneumonia
   Short Interest in Akari Therapeutics, Plc (NASDAQ:AKTX) Decreases By 74.4%  2021/11/29 06:30:47 Dakota Financial News
Akari Therapeutics, Plc (NASDAQ:AKTX) was the recipient of a significant drop in short interest during the month of November. As of November 15th, there was short interest totalling 15,700 shares, a drop of 74.4% from the October 31st total of 61,300 shares. Based on an average daily volume of 113,700 shares, the short-interest ratio is []
   Akari Therapeutics to Present at the Cantor Virtual Global Healthcare Conference  2021/09/22 13:00:00 Intrado Digital Media
NEW YORK and LONDON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that Clive Richardson, Chief Executive Officer, will present at the Cantor Virtual Global Healthcare Conference on Thursday, September 30, 2021 at 1:20 p.m. ET.
   Akari Therapeutics reports Q2 results  2021/09/22 12:43:36 Seeking Alpha
   Akari Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Clinical Progress  2021/09/22 12:30:00 Benzinga
Currently opening sites for Phase III study of nomacopan in bullous pemphigoid (BP). Phase III study of nomacopan in severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) open for enrollment. Evaluating the potential for long-acting PAS-nomacopan as a treatment for dry age-related macular degeneration (AMD). Collaborating with clinical partners to explore potential for treating exacerbations in severe lung diseases where inhaled nomacopan can be potentially delivered directly to the lung. Active pipeline exploring treatment of head trauma with nomacopan and the development of votucalis, a new anti-histamine biopharmaceutical with a similar structure to nomacopan. NEW YORK and LONDON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ: AKTX ), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced its financial results for the second quarter of 2021, as well as recent clinical progress.
   Akari Therapeutics to Present Its Phase III Plans for Nomacopan in Patients with Bullous Pemphigoid at the 2021 International Pemphigus & Pemphigoid Foundation (IPPF) Scientific Symposium  2021/09/10 12:30:34 Investor Akaritx
NEW YORK and LONDON, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated,
   Akari Therapeutics to Present Its Phase III Plans for Nomacopan in Patients with Bullous Pemphigoid at the 2021 International Pemphigus & Pemphigoid Foundation (IPPF) Scientific Symposium  2021/09/10 12:30:00 Intrado Digital Media
NEW YORK and LONDON, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that Miles Nunn, Ph.D., Chief Scientific Officer of Akari Therapeutics, and Sanjeev Khindri, M.D., Medical Director of Akari Therapeutics, will present a poster outlining the design of the Companys Phase III planned pivotal study of nomacopan in patients with moderate to severe bullous pemphigoid (BP) at the 2021 International Pemphigus & Pemphigoid Foundation (IPPF) Scientific Symposium.
   Akari Therapeutics to Present at the Cantor Virtual Global Healthcare Conference  2021/09/22 13:00:00 Intrado Digital Media
NEW YORK and LONDON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that Clive Richardson, Chief Executive Officer, will present at the Cantor Virtual Global Healthcare Conference on Thursday, September 30, 2021 at 1:20 p.m. ET.
   Akari Therapeutics reports Q2 results  2021/09/22 12:43:36 Seeking Alpha
   Akari Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Clinical Progress  2021/09/22 12:30:00 Benzinga
Currently opening sites for Phase III study of nomacopan in bullous pemphigoid (BP). Phase III study of nomacopan in severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) open for enrollment. Evaluating the potential for long-acting PAS-nomacopan as a treatment for dry age-related macular degeneration (AMD). Collaborating with clinical partners to explore potential for treating exacerbations in severe lung diseases where inhaled nomacopan can be potentially delivered directly to the lung. Active pipeline exploring treatment of head trauma with nomacopan and the development of votucalis, a new anti-histamine biopharmaceutical with a similar structure to nomacopan. NEW YORK and LONDON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ: AKTX ), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced its financial results for the second quarter of 2021, as well as recent clinical progress.
   Akari Therapeutics to Present Its Phase III Plans for Nomacopan in Patients with Bullous Pemphigoid at the 2021 International Pemphigus & Pemphigoid Foundation (IPPF) Scientific Symposium  2021/09/10 12:30:34 Investor Akaritx
NEW YORK and LONDON, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated,
   Akari Therapeutics to Present Its Phase III Plans for Nomacopan in Patients with Bullous Pemphigoid at the 2021 International Pemphigus & Pemphigoid Foundation (IPPF) Scientific Symposium  2021/09/10 12:30:00 Intrado Digital Media
NEW YORK and LONDON, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that Miles Nunn, Ph.D., Chief Scientific Officer of Akari Therapeutics, and Sanjeev Khindri, M.D., Medical Director of Akari Therapeutics, will present a poster outlining the design of the Companys Phase III planned pivotal study of nomacopan in patients with moderate to severe bullous pemphigoid (BP) at the 2021 International Pemphigus & Pemphigoid Foundation (IPPF) Scientific Symposium.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アカリ・セラピュ―ティクス AKTX Akari Therapeutics Plc)

 twitter  (公式ツイッターやCEOツイッターなど)